Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Glivec in advanced or metastatic DFSP/GCF with COL1A1/PDGFB rearrangement
2004-002538-20Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in dermatofibrosarcoma protuberans (DFSP) and giant cell fibroblastoma (GCF), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: 14-week progression-free survival. Started Mar 2005; status: completed.
02
Drugs
03
Conditions
dermatofibrosarcoma protuberans (DFSP)giant cell fibroblastoma (GCF)
Beyond the preview
Go deeper on 2004-002538-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002538-20.